MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
*Driving Forces: Market Research, Intelligence, Analysis, Datapoints, Databases & Trends
*Driving Forces: Pharmaceutical Development and Clinical Trials (Facts & Figures)
2018: The top 15 pharma companies by 2017 revenue
Amgen Inc. (NASDAQ:AMGN)
Organization & Developments: Amgen
*Developments: Amgen
Parents
Organization & Developments: Amgen
Children
2015: Amgen's deCODE lays marker for future of genomics-driven drug discovery
2016: Amgen Again Beats Regeneron And Sanofi In Court Over Repatha Patent Claims - DoctoRx
2016: Amgen Beats And Raises, The Street Yawns: An Analysis - Amgen Inc. (NASDAQ:AMGN)
2016: Amgen Beats, Raises Again: A Reassessment - Amgen Inc. (NASDAQ:AMGN)
2016: Amgen Gets Busy; Many News Items: Anything Good Yet? - Amgen Inc. (NASDAQ:AMGN)
2016: Amgen Is Even More Attractive After Earnings - Amgen Inc. (NASDAQ:AMGN)
2016: Amgen Is Melting Down - Amgen Inc. (NASDAQ:AMGN)
2016: Amgen: A Biotech Pioneer On Sale - Amgen Inc. (NASDAQ:AMGN)
2016: Biotech Forum Daily Digest: Can Biotech Rebound? Jefferies Says Sector Undervalued; Spotlight On Kite Pharma
2016: Ligand Pharma Adds Tech, Grows On Partners’ Success
2017: Can Xencor Continue To Rally? - Xencor, Inc. (NASDAQ:XNCR)
2017: Humana, Amgen team up on data-driven research venture
2017: Why One Drug Could Power Amgen To Finally Break To All-Time Highs By Next Year - Amgen Inc. (NASDAQ:AMGN)
2018: Your Daily Pharma Scoop: A Look At Advaxis, AstraZeneca's Positive Results, AbbVie Reports Q4 Results - Advaxis Inc. (NASDAQ:ADXS)
2019: Amgen is joining the biopharma exodus out of neurosciences R&D – Endpoints News
2019: Once spurned, Amgen wins the FDA over with its bone-building osteoporosis drug Evenity – Endpoints News
2020: Amgen taps Reify Health for better trial enrollment_fiercebiotech
2020: Amgen's big cardiovascular bet with Cytokinetics hits PhIII primary but dramatically disappoints investors
2020: Arrowhead Is A Buy On Takeda Deal And Massive Pipeline
2020: Pfizer, Amgen will rake in billions during ‘golden age’ for biosimilars: Analyst
2022: Amgen Vs. Mirati: Playing To Win In KRAS Mutated Lung Cancer_seekingalpha.com
2022: AMGN Amgen Q3 2022 - Earnings Call Slides (vFF)_ seekingalpha.com
2023: AbbVie, Anima Strike mRNA Deal Worth Up to $582
2023: Amgen Gives You Growth, Dividend Growth, And Value (NASDAQ:AMGN)
2023: Amgen Makes Early $2B Play to Boost ADC Portfolio
2023: Amgen: Wonderful Stock At Decent Price_ seekingalpha.com
2023: Revenue Headwinds Pull Amgen Into Neutral_ seekingalpha.com
2024: Amgen 2024: Building a portfolio with longevity
2024: Amgen Crashes 9% Despite 'Truly Remarkable' Results For Obesity Treatment
2024: Amgen Is A Fantastic Dividend Growth Stock With A Weight-Loss Wild Card
2024: Amgen Sells Off: Keep Calm And Buy The Dip
2024: Amgen: A Biotech Giant Offering Value And Growth In A Frothy Market_seekingalpha.com
2024: Amgen: An Emerging GLP-1 Play, Modest Mid-Teens P/E With Strong Momentum
2024: Amgen: Biotech Leader Riding High On Obesity Drug Euphoria (Downgrade)
2024: Amgen: Checks All The Wrong Boxes
2024: Amgen: Growth Is Still A Better Choice_ seekingalpha
2024: Amgen: I Prefer To Chase Value And Dividends_ seekingalpha.com
2024: Amgen: Pipeline Updates, Uplizna Performs And Rocatinlimab Underwhelms_
2024: Amgen: Q2 Earnings Review: Still Solid, But Wait For MariTide Data Goes On
2024: Amgen: The Giant With An Impressive Pipeline
2024: Amgen: Weight Loss Drug Candidate Debate A Red Herring - Buying The Dip Advisable
2024: Amgen: You Haven't Seen Anything Yet
2024: Amgen's obesity drug takes the weight off and may keep it off, too, early data suggest
2024: Amgen's Planning to Take a Bite Out of Cancer. Here's What It Means for the Stock.
2024: Hidden data on obesity prospect wipe $12B off Amgen market cap
2024: Move Over Eli Lilly: Amgen Could Be The Next Obesity Wonder Stoc
2024: Prescription For Dividends: Why Amgen Is More Than Just A Safe Bet
2024: Up 40%, 3%-Yielding Amgen Is Still One Of My Favorite Healthcare Stocks_ seekingalpha.com
2025: Amgen Q4 Earnings: Good Quarter, Ok Guidance, But MariTide Concerns Me (Rating Downgrade)
2025: Amgen Q4 Earnings: Strong Pipeline And Label Expansions Justify Buy Rating
2025: Amgen: Blockbusters, Emerging Therapies, And Investment Potential
2025: Amgen: Growth Potential Met By High Debt Levels
2025: Amgen: Riding The MariTide Of Monthly Weight Loss
2025: With patent losses on the horizon, Amgen refocuses its business strategy
2025: With patent losses on the horizon, Amgen refocuses its business strategy
Jumps
*Organization: Amgen
Developments: Amgen (Archives 2005-2014)